Guanidino compounds inhibit acetylcholinesterase and butyrylcholinesterase activities: Effect neuroprotector of vitamins E plus C

International Journal of Developmental Neuroscience

Volumn 28, Issue 6, 2010, Pages 465-473

  Delwing de Lima, Daniela ^b,c   Wollinger, Luiz Felipe ^a   Casagrande, Ana Carolina Mesquita ^a   Delwing, Fábio ^d   da Cruz, José Geraldo Pereira ^a   Wyse, Angela T S ^d   Delwing Dal Magro, Débora ^a  

^a REGIONAL UNIVERSITY OF BLUMENAU   (Brazil)

^b Universidade Comunitaria Regional de Chapeco   (Brazil)

^c DEPARTMENT OF FOOD ENGINEERING   (Brazil)

^d FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Cholinesterases; Guanidine compounds; Hyperargininemia; Oxidative stress and vitamins

Indexed keywords

ACETYLCHOLINESTERASE; ARGININE; ARGININIC ACID; ASCORBIC ACID; CHOLINESTERASE; GUANIDINE DERIVATIVE; HOMOARGININE; N ACETYLARGININE; TROLOX C; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BRAIN HOMOGENATE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; HIPPOCAMPUS; HYPERARGININEMIA; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ARGININE; ASCORBIC ACID; BUTYRYLCHOLINESTERASE; CHOLINESTERASE INHIBITORS; ENZYME ACTIVATION; HIPPOCAMPUS; NEUROPROTECTIVE AGENTS; RATS; RATS, WISTAR; VITAMIN E;

RATTUS;

EID: 77955426282     PISSN: 07365748     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijdevneu.2010.06.008     Document Type: Article

References (72)

1. Alcantara V.M., Chautard-Freire-Maia E.A., Scartezini M., Cerci M.S., Braun-Prado K., Picheth G. Butyrylcholinesterase activity and risk factors for coronary artery disease. Scand. J. Clin. Lab. Invest. 2002, 62:399-404.
2. Alvarez A., Opazo C., Alarcon R., Garrido J., Inestrosa N.C. Acetylcholinesterase promotes the aggregation of amyloid-beta-peptide fragments by forming a complex with the growing fibrils. J. Mol. Biol. 1997, 272:348-361.
3. Arendt T., Bruckner M.K., Lange M., Bigl V. Changes in acetylcholinesterase and butyrylcholinesterase in Alzeimer's disease resemble embryonic development-a study of molecular forms. Neurochem. Int. 1992, 21:381-396.
4. +-ATPase inhibition induced by arginine administration is prevented by vitamins E and C. Neurochem. Res. 2003, 28:825-829.
5. Benzi G., Moretti A. Is there a rationale for the use of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease?. Eur. J. Pharmacol. 1998, 346:1-13.
6. Blokland A. Acetylcholine: a neurotransmitter for learning and memory?. Brain Res. 1995, 21:285-300.
7. Bradford M.M. A rapid and sensitive method for the quantification of micrograms quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
8. Brusilow S.W., Horwich A. Urea cycle enzymes. The metabolic and Molecular Bases of Inherited Disease 2001, 1909-1963. McGraw-Hill, New York. 8th ed. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
9. Buettner G.R. The pecking order of free radicals and antioxidants: lipid peroxidation, alpha-tocopherol, and ascorbate. Arch. Biochem. Biophys. 1993, 300:535-543.
10. Burton G.W., Wronska U., Stone L., Foster D.O., Ingold K.U. Biokinetics of dietary RRR-α-tocopherol in the male guinea-pig at three dietary levels of vitamin C and two levels of vitamin E. Lipids 1990, 25:199-210.
11. Carr A., Frei B. Does Vitamin C act as a pro-oxidant under physiological conditions?. FASEB J. 1999, 13:1007-1024.
12. Colombo J.P. Argininaemia: clinical and biochemical aspects. Guanidines Compounds in Biology and Medicine 1992, vol. 1:343-347. John Libbey & Co., Guildford, UK.
13. Colome C., Sierra C., Vilaseca M.A. Congenital errors of metabolism: cause of oxidative stress?. Med. Clin. 2000, 115:111-117.
14. Cummings J.L. The role of cholinergic agents in the management of behavioral isturbances in Alzheimer's disease. Int. J. Neuropsychopharmacol. 2000, 3:21-29.
15. Darvesh S., Hopkins D.A., Geula C. Neurobiology of butyrylcholinesterase. Nat. Rev. Neurosci. 2003, 4:131-138.
16. De Deyn P.P., Macdonalds R.L. Guanidino compounds that are increased in uremic patients inhibit GABA- and glycine-responses on mouse neurons in cell culture. Ann. Neurol. 1990, 28:627-633.
17. De Deyn P.P., Marescau B., Macdonald R.L. Guanidino compounds that are increased in hyperargininemia inhibit GABA and glycine responses on mouse neurons in cell culture. Epilepsy Res. 1991, 8:134-141.
18. De Deyn P.P., D'Hooge R., Marescau B., Pei Y.K. Chemical models of epilepsy and their applicability in the development of anticonvulsants. Epilepsy Res. 1992, 12:87-110.
19. De Deyn P.P., Marescau B., Qureshi I.A., Cederbaum S.D., Lambert M., Cerone R., Chamoles N., Speócola N., Leonard J.V., Gatti R., Kang S.S., Mizutani N., Rezvani I., Snyderman S.E., Terheggen H.G., Yoshino M., Appel B., Martin J.J., Beaudet A.L., Vilarinho L., Hirrsch E., Jakobs K., van der Knaap M.S., Naito H., Pickut B.A., Shapira S.K., Fuchshuber A., Roth B., Hylan K. Hyperargininemia: a treatable inborn error of metabolism?. Guanidino Compounds in Biology and Medicine 1997, vol. 2:53-69. John Libbey & Co., Guildford, UK.
20. Delwing D., Delwing D., Wannamacher C.M.D., Wajner M., Dutra-Filho C.S., Wyse A.T.S. Arginine administration reduces catalase activity in midbrain of rats. NeuroReport 2002, 13:1301-1304.
21. Delwing D., Tagliari B., Streck E.L., Wannamacher C.M.D., Wajner M., Wyse A.T.S. Reduction of energy metabolism in rat hippocampus by aginine administration. Brain Res. 2003, 983:58-63.
22. Delwing D., Chiarani F., Delwing D., Bavaresco C.S., Wannmacher C.M.D., Wajner M., Wyse A.T.S. Proline reduces acetylcholinesterase activity in cerebral cortex of rats. Metab. Brain Dis. 2003, 18:79-86.
23. Delwing D., Gonçalves M.C.F., Sarkis J.J.F., Wyse A.T.S. l-NAME administration prevents the inhibition of nucleotide hydrolysis by rat blood serum subjected to hyperargininemia. Amino Acids 2005, 29:267-272.
24. Delwing D., Tagliari B., Chiarani F., Wannmacher C.M.D., Wajner M., Wyse A.T.S. α-Tocopherol and ascorbic acid administration prevents the impairment of brain energy metabolism of hyperargininemic rats. Cell. Mol. Neurobiol. 2006, 26:177-189.
25. Delwing D., Delwing D., Bavaresco C.S., Wyse A.T.S. Protective effect of nitric synthase inhibition or antioxidants on brain oxidative damage caused by intracerebroventricular arginine administration. Brain Res. 2007, 1193:120-127.
26. Delwing D., Cornélio A.R., Wajner M., Wannmacher C.M.D., Wyse A.T.S. Arginine administration reduces creatine kinase activity in rat cerebellum. Metab. Brain Dis. 2007, 22:13-23.
27. D'Hooge R., Manil J., Colin F., De Deyn P.P. Guanidinosuccinic acid inhibits excitatory synaptic transmission in CA1 region of rat hippocampal slices. Ann. Neurol. 1991, 30:622-623.
28. D'Hooge R., Raes A., Lebrun P., Diltoer M., Van Bogaert P.P., Manil J., Colin F., De Deyn P.P. Neural excitation by uremic guanidine compounds. Guanidino Compounds in Biology and Medicine 1997, vol. 2:349-357. John Libbey & Co., Guildford, UK.
29. Ellman G.L., Courtney K.D., Andres V., Feather-Stone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 1961, 7:88-95.
30. Fishman E.B., Siek G.C., MacCallum R.D., Bird E.D., Volicer L., Marqui J.K. Distribution of the molecular forms of acetylcholinesterase in human brain: alterations in dementia of the Alzheimer type. Ann. Neurol. 1986, 19:246-252.
31. Frei B., Stocker R., England L., Ames B.N. Ascorbate: the most effective antioxidant in the blood. Adv. Exp. Med. Biol. 1990, 264:155-163.
32. Geula C., Mesulam M.M., Kuo C.C., Tokuno H. Postnatal development of cortical acetylcholinesterase-rich neurons in the rat brain: permanent and transient patterns. Exp. Neurol. 1995, 134:157-178.
33. Geula C., Darvesh S. Butyrylcholinesterase, cholinergic neurotransmission and the pathology of Alzheimer's disease. Drugs Today 2004, 40:711-721.
34. Gómez-Ramos P., Morán M.A. Ultra structural localization of butyrylcholinesterase in senile plaques in the brains of aged and Alzheimer's disease patients. Mol. Chem. Neuropathol. 1997, 30:161-173.
35. Grafius M.A., Bond H.E., Millar D.B. Acetylcholinesterase interaction with a lipoprotein matrix. Eur. J. Biochem. 1971, 22:382-390.
36. Halliwell B., Gutteridge J.M.C. Free Radicals in Biology and Medicine 1999, Oxford University Press, London.
37. Henderson V.W., Watt L., Buckwalter J.G. Cognitive skills associated with estrogen replacement in women with Alzeimer's disease. Psychoneuroendocrinology 1996, 21:421-430.
38. Hiramatsu M., Ohba S., Edamatsu R., Kadowari D., Mori A. Effect of guanidino compounds on membrane fluidity of rat synaptosomes. Guanidino Compounds in Biology and Medicine 1992, vol. 1:387-393. John Libbey, Guildford, UK.
39. Iyer R., Jenkinson C.P., Vockley J.G., Kern R.M., Grody W.W., Cederbaum S. The human arginases and arginase deficiency. J. Inherit. Metab. Dis. 1998, 21:86-100.
40. Law A., Gauthier S., Quirion R. Say NO Alzheimer's disease: the putative links between nitric oxide and dementia of the Alzheimer's type. Brain Res. Rev. 2001, 35:73-96.
41. Magarian E.O., Dietz A.J. Correlation of cholinesterase with serum lipids and lipoproteins. J. Clin. Pharmacol. 1987, 27:819-820.
42. Marescau B., Qureshi I.A., De Deyn P.P., Letarte J., Ryba R., Lowenthal A. Guanidino compounds in plasma, urine and cerebrospinal fluid of hyperargininemic patients during therapy. Clin. Chim. Acta 1985, 146:21-27.
43. Marescau B., De Deyn P.P., Lowenthal A., Qureshi I.A., Antonozzi I., Backmann C., Cederbaum S.D., Cerone N., Chamoles N., Colombo J.P., Hyland K., Gatti R., Kang S.S., Letarte L., Lambert M., Minutani N., Possemiers I., Rezvani I., Snyderman S.E., Terheggen H.G., Yoshino M. Guanidino compounds analysis as a complementary diagnostic parameter for hyperargininemia: follow-up of guanidine compounds levels during therapy. Pediatr. Res. 1990, 27:297-303.
44. Marescau B., Deshmukh D.R., Kockx M., Possemiers I., Qureshi I.A., Wiechert P., De Deyn P.P. Guanidino compounds in serum, urine, liver, kidney and brain of man and some urotelic animals. Metabolism 1992, 41:526-532.
45. Massoulie J., Pezzementi L., Bon S., Krejci E., Vallette F.M. Molecular and cellular biology of cholinesterases. Prog. Neurobiol. 1993, 41:31-91.
46. Matsumoto M., Kobayashi K., Kishikawa H., Mori A. Convulsive activity of methylguanidine in cat and rabbits. IRCS Med. Sci. 1976, 4:65.
47. Melo J.B., Agostinho P., Oliveira C.R. Involvement of oxidative stress in the enhancement of acetylcholinesterase activity induced by amyloid beta-peptide. Neurosci. Res. 2003, 45:117-127.
48. Mesulam M.M., Guillozet A., Shaw P., Levey A., Duysen E.G., Lockridge O. Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyse acetylcholine. Neuroscience 2002, 170:627-639.
49. Monteiro S.C., Stefanello F.M., Vianna L.P., Matté C., Barp J., Belló-Klein A., Trindade V.M.T., Wyse A.T.S. Ovariectomy enhances acetylcholinesterase activity but does not alter ganglioside content in cerebral cortex of female adult rats. Metab. Brain Dis. 2005, 20:35-44.
50. Mori A. Biochemistry and neurotoxicity of guanidino compounds. History and recent advances. Pavlov. J. Biol. Sci. 1987, 22:85-94.
51. OóBrien K.K., Saxby B.K., Ballard C.G., Grace J., Harrington F., Ford G.A., OóBrien J.T., Swan A.G., Fairbairn A.F., Wesnes K., del Ser T., Edwardson J.A., Morris C.M., McKeith I.G. Regulation of attention and response to therapy in dementia by butyrylcholinesterase. Pharmacogenetics 2003, 13:231-239.
52. Petersen R.C., Smith G.E., Waring S.C., Ivnik R.J., Tangalos E.G., Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 1999, 56:303-308.
53. Picot I.C., Trivier J.M., Nicole A., Sinet P.M., Thevenin M. Age-correlated modifications of copper-zinc superoxide dismutase and glutathione-related enzyme activities in human erythrocytes. Clin. Chem. 1992, 38:66-70.
54. +-ATPase activity and impairs retention of an inhibitory avoidance task in rats. Brain Res. 2002, 951:151-157.
55. Schreier S., Polnazek C.F., Smith I.C.P. Spin labels in membrane: problem in practice. Biochim. Biophys. Acta 1978, 553:84-95.
56. Shiraga H., Hiramatsu M., Mori A. Convulsive activity of α-guanidino glutaric acid and the possible involvement of 5-hydroxy-tryptamine in the a-guanidino glutaric acid induced seizure mechanism. J. Neurochem. 1986, 47:1832-1836.
57. Silva C.G., Parolo E., Streck E.L., Wajner M., Wannmacher C.M.D., Wyse A.T.S. In vitro inhibition of Na, K -ATPase activity from rat cerebral cortex by guanidino compounds accumulating in hyperargininemia. Brain Res. 1999, 838:78-84.
58. Silva C.G., Bueno A.R.F., Schuck P.F., Leipnitz G., Ribeiro C.A., Rosa R.B., Dutra Filho C.S., Wyse A.T., Wannmacher C.M., Wajner M. Inhibition of creatine kinase activity from rat cerebral cortex by D-2-hydroxyglutaric acid in vitro. Neuchem. Int. 2004, 44:45-52.
59. Silver A. The Biology of Cholinesterases 1974, North-Holland, Amsterdam.
60. Stefanello F.M., Monteiro S.C., Matté C., Scherer E.B.S., Netto C.S., Wyse A.T.S. Hypermethioninemia increases cerebral acetylcholinesterase activity and impairs memory in rats. Neurochem. Res. 2007, 32:1868-1874.
61. Tsakiris S., Angelogianni P., Schulpis K.H., Stavridis J.C. Protective effect of l-phenylalanine on rat brain acetylcholinesterase inhibiton induced by free radicals. Clin. Biochem. 2000, 33:103-106.
62. Van Backel M.M., Printzen G., Wermuth B., Wiesmann U.N. Antioxidant and thyroid hormone status in selenium-deficient phenylketonuric and hyperphenylalaninemic patients. Am. J. Clin. Nutr. 2000, 72:976-981.
63. Van Biesen W., De Bacquer D., Verbeke F., Delanghe J., Lameire N., Vanholder R. The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years. Eur. Heart J. 2007, 28:478-483.
64. Vanholder R., Massy Z., Argiles A., Spasovski G., Verbeke F., Lameire N. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol. Dial. Transplant. 2005, 20:1048-1056.
65. Wajner M., Latini A., Wyse A.T.S., Dutra-Filho C.S. The role of oxidative damage in the neuropathology of organic acidurias: insights from animal studies. J. Inherit. Metab. Dis. 2004, 27:427-448.
66. Wierchert P., Marescau B., De Deyn P.P., Lowenthal A. Guanidino compounds in serum and brain of audiogenic sensitive rats during the preconvulsive running phase of cerebral seizures. Neuroscience 1987, 13:35-40.
67. +-ATPase activity in midbrain of rats subjected to arginine administration. Neurochem. Res. 2001, 26:515-520.
68. Wyse A.T.S., Bavaresco C.S., Hagen M.E.K., Delwing D., Wannmacher C.M.D., Dutra-Filho C.S., Wajner M. In vitro stimulation of oxidative stress in cerebral cortex of rats by the guanidine compounds accumulating in hyperargininemia. Brain Res. 2001, 923:50-57.
69. +-ATPase activity in hippocampus of rats subjected to acute administration of homocysteine is prevented by vitamins E and C treatment. Neurochem. Res. 2002, 27:1685-1689.
70. Wyse A.T.S., Stefanello F.M., Chiarani F., Delwing D., Wannmacher C.M.D., Wajner M. Arginine administration decreases cerebral cortex acetylcholinesterase and serum butyrylcholinesterase probably by oxidative stress induction. Neurochem. Res. 2004, 29:385-389.
71. Yokoi I., Toma J., Mori A. The effect of homoarginine on the EEG of rats. Neurochem. Pathol. 1984, 2:295-300.
72. Younkin S.G., Goodridge B., Katz J., Lockett G., Nafziger D., Usiak M.F., Younkin L.H. Molecular forms of acetylcholinesterases in Alzheimer's disease. Fed. Proc. 1986, 45:2982-2988.